Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Cyclosporine in the treatment of azathioprine-induced red cell aplasia following renal transplantation

  • 16 Accesses

  • 4 Citations

Abstract

Azathioprine, a well-known immunosuppressive agent, is used extensively in renal transplantation. There have been several case reports of pure red cell aplasia induced by this drug following a successful kidney transplant. Previous management of azathioprine-induced red cell aplasia included reduction of azathioprine dose, or treatment with cyclophosphamide. We propose the substitution of cyclosporine for azathioprine, in this clinical setting. Not only does cyclosporine allow recovery of bone marrow function, but it maintains a level of immunosuppression which stabilizes renal function in the post-transplant patient.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Bach JB, Dardenne M (1971) The metabolism of azathioprine in renal failure. Transplantation 12: 253–259

  2. 2.

    Klippel JH, Decker JL (1974) Relative macrocytosis in cyclophosphamide and azathioprine therapy. JAMA 229: 180–181

  3. 3.

    Wickramasighe SN, Dodsworth H, Rault RMJ, Hulme B (1974) Observations on the incidence and cause of macrocytosis in patients on azathioprine therapy following renal transplant. Transplantation 18: 443–446

  4. 4.

    McGrath BP, Ibels LS, Raik E, Hargrave M, Mahony JF, Stewart JH (1975) Erythroid toxicity of azathioprine: macrocytosis and selective marrow hypoplasia. QJ Med 44: 57–63

  5. 5.

    DeClerck YA, Ettenger RB, Orkga JA, Pennisi AJ (1980) Macrocytosis and pure RBC anemia caused by azathioprine. Am J Dis Child 134: 377–379

  6. 6.

    Old CW, Flannery EP, Grogan TM, Stone WH, SanAntonio RP (1978) Azathioprine-induced pure red cell aplasia. JAMA 240: 552–554

  7. 7.

    Hogge DE, Wilson DR, Shumat KH, Caltram DC (1982) Reversible azathioprine-induced erythrocyte aplasia in a renal transplant recipient. Can Med Assoc J 126: 512–513

  8. 8.

    Handschumacher RE (1990) Immunosuppressive drug. In: Goodman L, Gilman A, Rall TW, Nies AS, Taylor P (eds) The pharmacological basis of therapeutics, 8th edn. Pergamon, New York, pp 1264–1276

  9. 9.

    Alexander SR, Arbus GS, Butt KMH, Conley S, Fine RN, Greifer I, Gruskin AB, Harmon WE, McEnery PT, Nevins TE, Nogueira N, Salvatierra O, Tejani A (1990) The 1989 report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol 4: 542–553

  10. 10.

    Kahan BD (1989) Cyclosporine. N Engl J Med 321: 1725–1738

  11. 11.

    Penn I (1987) Cancers following cyclosporine therapy. Transplantation 43: 32–35

Download references

Author information

Correspondence to Barbara A. Fivush.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Vogt, B., Fivush, B.A. Cyclosporine in the treatment of azathioprine-induced red cell aplasia following renal transplantation. Pediatr Nephrol 6, 278–279 (1992). https://doi.org/10.1007/BF00878378

Download citation

Key words

  • Red cell aplasia
  • Azathioprine
  • Cyclosporine
  • Renal transplantation
  • Immunosuppression